Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

NLM Logo

nimotuzumab MeSH Supplementary Concept Data 2026


MeSH Supplementary
nimotuzumab
Unique ID
C501466
RDF Unique Identifier
http://id.nlm.nih.gov/mesh/C501466
Entry Term(s)
Theraloc
theracim-HR3
Pharm Action
Antineoplastic Agents, Immunological
Registry Numbers
6NS400BXKH
CAS Type 1 Name
Immunoglobulin G1, anti-(humanized mouse monoclonal hR3 beta1 chain anti-human epidermal growth factor receptor), disulfide with humanized mouse monoclonal hR3 kappa-chain, dimer
Previous Indexing
*ANTIBODIES, MONOCLONAL (2005-2011)
Heading Mapped to
*Antibodies, Monoclonal, Humanized
Frequency
218
Note
a humanized monoclonal antibody that binds to the epidermal growth factor receptor
Source
Curr Opin Mol Ther 2005 Apr;7(2):182-91
Date Introduced
2005/06/23
Last Updated
2019/10/31
nimotuzumab Preferred
Theraloc Narrower
theracim-HR3 Narrower
page delivered in 0.007s